Spotlight on IONIS-FB-LRx – Systemic Administration of a RNA-Targeting Therapeutic for GA

Time: 12:15 pm
day: Track 2 Day 1 AM


  • Discuss the novel approach for addressing systemic etiologies of GA
  • Examine the clinical utility of Antisense (ASO) therapeutics for common and rare diseases
  • Analyses of complement regulation in Phase 1 studies with the factor B ASO
  • Update on ongoing Ph 2 GA trial, the GOLDEN Study